Metformin May Not Benefit Non-Diabetic Heart Patients

Published Online: Tuesday, December 17, 2013
Follow Pharmacy_Times:
Although metformin has been shown to reduce cardiovascular risk in patients with type 2 diabetes mellitus, new research finds that the drug may not offer the same protective benefits in those without diabetes.

The study, published online on November 7, 2013, in The Lancet Diabetes & Endocrinology, randomly assigned 173 patients—who had coronary heart disease and large waist circumferences, were taking statins, and did not have diabetes—to take metformin 850 mg or placebo twice daily.

The researchers measured the progression of mean distal carotid intima-media thickness, changes in carotid plaque scores, measures of glycemia, and concentration of lipids.

After 18 months, carotid intima-media thickness progressed similarly among patients in the metformin and placebo groups. There was no significant difference in changes in carotid plaque scores between the groups as well. Total cholesterol, high-density lipoprotein (HDL)–cholesterol, non-HDL-cholesterol, triglycerides, and fasting glucose levels also did not differ significantly between patients assigned to metformin and those assigned to placebo. Patients taking metformin did, however, have significantly lower glycated hemoglobin and insulin levels compared with those taking the placebo. Diarrhea, nausea, and vomiting were more common among the metformin group than the placebo group.

The study was limited by a small sample size and short follow-up, and the researchers suggest that larger studies are needed to confirm the results.

Related Articles
The lack of generic insulin may keep patients from using the medicine, even though they risk life-threatening complications, new research from Johns Hopkins University School of Medicine suggests.
An FDA advisory panel recommends adding a warning about the potential risk for heart failure to the labels of saxagliptin (Onglyza), saxagliptin/metformin (Kombiglyze), and alogliptin (Nesina).
The FDA refused to approve Novo Nordisk’s ultra-long-acting insulin treatments 2 years ago.
Patrick Curtin, PharmD, BCPS, Clinical Coordinator at Overlook Medical Center in Summit, New Jersey, provides some basics about nonstatin therapy.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$